

Press briefing 3

Monday, 29 September 2014, 8:15-9:00 (CEST)

Moderator: Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium

Programme

The data presented will refer to the following studies:

<p>LBA3 A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy</p>	<p>Jeffrey Weber, H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States</p>
<p>LBA5 Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated BRAFV600 Mutation–Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (NCT01689519)</p>	<p>Grant McArthur, Peter MacCallum Cancer Centre, Melbourne, Australia</p>
<p>LBA4 COMBI-v: A randomised, open-label, Phase III study comparing the combination of dabrafenib and trametinib to vemurafenib as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma</p>	<p>Caroline Robert, Gustave Roussy, Villejuif, France</p>
<p>LBA37 Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy: final results of the randomized multicenter phase II trial SAKK17/04</p>	<p>Rolf Stahel, Universitätsspital Zürich, Zürich, Switzerland</p>

Data presented at this Press Conference is embargoed until Monday, 29 September 2014 at 9:00 CEST



Journalists quiz the experts

Monday, 29 September 2014, 16:30-18:00 (CEST)

Moderator: Franco Cavalli, European School of Oncology (ESO) Scientific Chair, Milan, Italy

Speakers: Cora Sternberg, Head of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy; Marek Kania, VP Medical Affairs Lilly Oncology; Jan Geissler, Chronic Myeloid Leukaemia; José Martin Moreno, former Director General of Public Health & Chief Medical Officer of Spain

Programme

Within the framework of an ESO-initiated training, journalists will have the chance to quiz representatives from the industry, health policy, medical oncology and patient advocacy about the reality of patient access to state-of-the-art cancer care in Europe's overstretched healthcare systems.

Speakers will be given 10 minutes each for an initial presentation, leaving more than one hour for questions and discussion.